Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy

E-ISSN： 1097-0142|120|16|2403-2411

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.16, 2014-08, pp. : 2403-2411

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data

By Ellis Matthew J. Rigden Caron E.

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2479-2487

Informa Healthcare

Access to resources Recommend Favorite

Patient‐reported outcomes of dental implant therapy in a large randomly selected sample

CLINICAL ORAL IMPLANTS RESEARCH, Vol. 26, Iss. 5, 2015-05 ,pp. : 586-591

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy‐induced amenorrhea

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 68, Iss. 1, 2018-01 ,pp. : 5-6

John Wiley & Sons Inc

Access to resources Recommend Favorite

Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review

Psychotherapy and Psychosomatics, Vol. 84, Iss. 2, 2015-02 ,pp. : 72-81

Karger

Access to resources Recommend Favorite

Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms

By Serels Scott R. Toglia Marc R. Forero-Schwanhaeuser Sergio He Weizhong

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2277-2285

Informa Healthcare

Access to resources Recommend Favorite